Get to know our clinical trials

Clinical trial of AMG 160 in combination with abiraterone in subjects with metastatic castration-resistant prostate cancer (mCRPC)

THIS STUDY IS PERFORMED TO FURTHER INVESTIGATE AMG 160 IN COMBINATION WITH ABIRATERONE IN MEN WITH MCRPC. THE STUDY WILL CONSIST OF 2 PARTS. PART 1: THE OBJECTIVE OF PART 1 IS TO DETERMINE WHETHER AMG 160 IN COMBINATION WITH ABIRATERONE IS SAFE AND TOLERABLE AND WHETHER IT CAUSES ANY SIDE EFFECTS. THIS STUDY WILL ALSO EVALUATE WHICH DOSES OF AMG 160 IN COMBINATION WITH ABIRATERONE ARE SAFE FOR ADMINISTRATION IN MEN AND ITS EFFECT ON MCRPC. PART 2: THE OBJECTIVE OF PART 2 IS TO DETERMINE WHETHER THE SELECTED DOSE OF AMG 160 FROM PART 1 IN COMBINATION WITH ABIRATERONE IS SAFE AND TOLERABLE AND WHETHER IT CAUSES ANY SIDE EFFECTS.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE 1B STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AMG 160 IN COMBINATION WITH ABIRATERONE IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).
  • Code EudraCT: 2020-001305-23
  • Protocol number: 20190505
  • Promoter: Amgen, S.A.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.